Telix reports Phase 1 ProstACT SELECT results for TLX591-Tx in prostate cancer

The company said the study showed TLX591-Tx was safe and effective in advanced metastatic prostate cancer when patients were selected using 68Ga-PSMA-PET/CT imaging.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.